The European Commission declared on Friday it has struck a deal with French pharmaceutical giant Sanofi to book 300 million doses of a potential future COVID-19 vaccine.
The arrangement will offer an alternative for the many EU Member States to buy the vaccine.
President of the European Commission Ursula von der Leyen explained: “While we don’t know now which vaccine will probably operate best in the long run, Europe is investing in a diversified portfolio of promising vaccines, based on several different forms of technologies.
“This raises our odds to obtain rapidly an effective treatment against the virus.”
The vaccine candidate, developed by Sanofi in partnership with GSK, relies on the recombinant protein technologies that Sanofi utilized to create a flu vaccine and about the adjuvant for pandemic usage developed by GSK. The doses could be produced in Western countries and specifically in France, Belgium, Germany, and Italy.
Sanofi is leading clinical development and vaccine enrollment processes and strategies to start a Phase I / II study in September, followed by a Phase III study from the end of 2020. If the information is favorable, regulatory acceptance for this particular vaccine could be gotten in the first half of 2021.
In the same period, Sanofi and GSK are raising their antigen and adjuvant manufacturing capabilities to have the ability to produce up to a billion doses each year in total.
The Commission is now negotiating with many vaccine developers to strike similar deals, ” it said, adding it is about to team up with global partners in case a”large number of nations could agree to pool funds for collectively reserving future offenses from firms such as themselves” and to get low-income and low countries in precisely the same moment.
It further says, “the high-income nations could function as an inclusive foreign buyers’ group, thereby hastening the development of safe and effective vaccines and increase accessibility to them for those who need it around the globe.”
By Sanofi Pasteur welcomed the arrangement with the European Union, stating: “We’ve always been dedicated to providing an inexpensive vaccine that’s available to all and are thankful to the European Commission because of its continuing commitment to both sides and its service.”
A couple of hours before the European statement, Sanofi and also the British lab GSK announced they would get around $ 2.1 billion to the growth of their possible anti-COVID-19 vaccine, even after being chosen to provide 100 million doses to Americans.
The French authorities welcomed the Commission’s statement, that”will make it possible for each member nation of the European Union to dictate the embryo on favorable terms , after it has given adequate proof of its effectiveness and’lack of side impacts”.